SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001127602-19-001579
Filing Date
2019-01-08
Accepted
2019-01-08 13:20:22
Documents
2
Period of Report
2019-01-04

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT form3.html 3  
1 PRIMARY DOCUMENT form3.xml 3 1351
2 POWER OF ATTORNEY (PUBLIC): EXHIBIT 24 - POWER OF ATTORNEY doc1.txt EX-24 3833
  Complete submission text file 0001127602-19-001579.txt   6555
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Issuer) CIK: 0000882796 (see all company filings)

IRS No.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 6300 DUMBARTON CIRCLE FREMONT CA 94555
Business Address
ASELAGE STEVE (Reporting) CIK: 0001221599 (see all company filings)

Type: 3 | Act: 34 | File No.: 000-23186 | Film No.: 19515428